



Clinical utility proven in screening by invitation

A prospective, population-based, randomized clinical utility study (N=12,750) published in the Lancet Oncology. The study showed that Stockholm3+MRI reduced over-detection, MRIs and biopsies, maintaining the same or higher sensitivity compared to PSA in a screening by invitation program.

Key conclusions were that i) Stockholm3 test can inform risk stratification before MRI and targeted biopsies in prostate cancer screening and that ii) combining Stockholm3 with an MRI-targeted biopsy approach for prostate cancer screening decreases over-detection while maintaining the ability to detect clinically significant cancer.



THE LANCET
Oncology

“An important step towards smarter screening for prostate cancer”¹⁰



“... Stockholm3 blood test trial results are seminal”¹¹

EAU22

EAU prostate
Cancer Award 2022

A3P Biomedical

A3P Biomedical AB (publ)
Kungsgatan 24
111 35 Stockholm | Sweden

www.a3p.com
info@a3p.com

References

- Bergman et al. Strukturerat omhändertagande för män som önskar prostatacancerdiagnostik erfarenheter från Prostatacancercentrum. Läkartidningen. 2018. Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018. Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. SJPHC. 2020.
- Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology. 2015. Bergman et al. Strukturerat omhändertagande för män som önskar prostatacancerdiagnostik erfarenheter från Prostatacancercentrum. Läkartidningen. 2018. Grönberg et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology. 2018. Eklund et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. European Urology Focus. 2016.
- Key large study publications include: Grönberg et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015. Nordström et al. Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies. The Lancet Oncology. 2021. Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. SJPHC. 2020.
- Swedish National Prostate Cancer Register (NCPR), 2018-2019.
- Figures in relation to Sweden overall.
- Bergman et al. Strukturerat omhändertagande för män som önskar prostatacancerdiagnostik erfarenheter från Prostatacancercentrum. Läkartidningen. 2018.
- Viste et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. SJPHC. 2020.
- Nordström et al. Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies. The Lancet Oncology. 2021.
- Hao et al. Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. European Urology. 2022.
- Moore. An important step towards smarter screening for prostate cancer. The Lancet Oncology. 2021.
- Hay. Stockholm3 tests improve prostate cancer screening. Cancer. 2021.

Stockholm3 test

THE FUTURE OF
PROSTATE CANCER
DIAGNOSTICS

A3P
Biomedical

Stockholm3 test


Radically improves early detection of prostate cancer

- ✓ **Stockholm3 finds twice as many men** with aggressive cancers compared to current clinical practice with PSA¹
- ✓ **Stockholm3 decreases the number of unnecessary biopsies by 50%** compared to current clinical practice with PSA²
- ✓ **Stockholm3 finds aggressive cancer also in men with low PSA values**
- ✓ **Stockholm3 is based on scientific clinical studies including more than 75,000 men**³
- ✓ **Stockholm3 has been used in clinical practice in Sweden and Norway since 2017**



Stockholm3 combines proteins, genetics and clinical data into an easy to interpret risk score

Stockholm3 combines protein markers (free and total PSA, PSP94, GDF15 and KLK2), genetic markers (101 SNPs), and clinical data (age, family history of prostate cancer, previous biopsies, use of 5-alpha reductase inhibitors) in an algorithm with the purpose of detecting aggressive prostate cancer at an early stage.




Clinical utility proven in routine care

Stockholm3 has enabled Capio S:t Görän Hospital and Helse Stavanger to improve clinical outcomes and reduce cost.

Capio S:t Görän outperforms all other prostate cancer clinics in Sweden

Distribution of risk group at primary diagnostics (N=21,135)⁴




17%
COST REDUCTION⁶

- ✓ One of Stockholm's major care providers covering 35% of all prostate cancer diagnostics and care in Region Stockholm
- ✓ Replaced PSA by Stockholm3 in 2017

Helse Stavanger improved clinical outcome

Increased sensitivity and specificity (N=4,784)⁷



23-28%
COST REDUCTION⁷

- ✓ Covering all prostate cancer diagnostics and care in Region Rogaland, Norway, with ~350,000 inhabitants
- ✓ Replaced PSA by Stockholm3 in 2019